Riley MB - Search Results

1

Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older.

Nabhan C, Rundhaugen LM, Riley MB, Rademaker A, Boehlke L, Jatoi M, Tallman MS. Nabhan C, et al. Among authors: riley mb. Leuk Res. 2005 Jan;29(1):53-7. doi: 10.1016/j.leukres.2004.04.011. Leuk Res. 2005. PMID: 15541475 Clinical Trial.

2

Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.

Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, Frater JL, Tallman MS. Parmar S, et al. Leuk Res. 2004 Sep;28(9):909-19. doi: 10.1016/j.leukres.2003.12.012. Leuk Res. 2004. PMID: 15234567 Clinical Trial.

3

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, Rosen ST. Nabhan C, et al. Among authors: riley mb. Leuk Lymphoma. 2004 Nov;45(11):2269-73. doi: 10.1080/10428190412331286096. Leuk Lymphoma. 2004. PMID: 15512816 Clinical Trial.

4

Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease.

Nabhan C, Rundhaugen L, Jatoi M, Riley MB, Boehlke L, Peterson LC, Tallman MS. Nabhan C, et al. Among authors: riley mb. Ann Oncol. 2004 Aug;15(8):1231-6. doi: 10.1093/annonc/mdh324. Ann Oncol. 2004. PMID: 15277263 Free article.

5

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.

Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC. Frater JL, et al. Among authors: riley mb. Am J Clin Pathol. 2003 Jun;119(6):833-41. doi: 10.1309/A4RG-P4LF-12GG-H8MW. Am J Clin Pathol. 2003. PMID: 12817431 Clinical Trial.

6

Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma.

Enschede SH, Shahidi H, Venugopal P, Riley MB, Huang R, Jajeh A, Preisler HD, Gregory SA. Enschede SH, et al. Among authors: riley mb. Leuk Lymphoma. 2001 Jan;40(3-4):325-34. doi: 10.3109/10428190109057931. Leuk Lymphoma. 2001. PMID: 11426554 Clinical Trial.

7

Ibritumomab tiuxetan.

Riley MB. Riley MB. Clin J Oncol Nurs. 2003 Jan-Feb;7(1):110-2. doi: 10.1188/03.CJON.109-112. Clin J Oncol Nurs. 2003. PMID: 12629947 No abstract available.

8

Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

Riley MB, Gordon LI. Riley MB, et al. Semin Oncol Nurs. 2004 Feb;20(1 Suppl 1):8-13. doi: 10.1053/j.soncn.2004.02.008. Semin Oncol Nurs. 2004. PMID: 15160856 Review.

9

The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-Hodgkin's lymphoma.

Riley MB, Byar K. Riley MB, et al. Semin Oncol Nurs. 2004 Feb;20(1 Suppl 1):1-7. doi: 10.1053/j.soncn.2004.02.007. Semin Oncol Nurs. 2004. PMID: 15160855 Review.

10

Neuronal Ndst1 depletion accelerates prion protein clearance and slows neurodegeneration in prion infection.

Aguilar-Calvo P, Malik A, Sandoval DR, Barback C, Orrù CD, Standke HG, Thomas OR, Dwyer CA, Pizzo DP, Bapat J, Soldau K, Ogawa R, Riley MB, Nilsson KPR, Kraus A, Caughey B, Iliff JJ, Vera DR, Esko JD, Sigurdson CJ. Aguilar-Calvo P, et al. Among authors: riley mb. PLoS Pathog. 2023 Sep 25;19(9):e1011487. doi: 10.1371/journal.ppat.1011487. eCollection 2023 Sep. PLoS Pathog. 2023. PMID: 37747931 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51 results

Search Page